Artiva Biotherapeutics (NASDAQ:ARTV) Receives “Buy” Rating from Needham & Company LLC

Needham & Company LLC restated their buy rating on shares of Artiva Biotherapeutics (NASDAQ:ARTV) in a report issued on Wednesday,Benzinga reports. They currently have a $23.00 target price on the stock.

Several other equities research analysts also recently issued reports on the stock. Jefferies Financial Group began coverage on shares of Artiva Biotherapeutics in a research note on Tuesday, August 13th. They issued a “buy” rating and a $21.00 price objective on the stock. Cantor Fitzgerald assumed coverage on Artiva Biotherapeutics in a research report on Tuesday, August 13th. They issued an “overweight” rating and a $23.00 price target on the stock. Wedbush reissued an “outperform” rating and issued a $18.00 target price on shares of Artiva Biotherapeutics in a report on Friday, August 30th. Finally, TD Cowen started coverage on shares of Artiva Biotherapeutics in a report on Tuesday, August 13th. They set a “buy” rating on the stock. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat, Artiva Biotherapeutics presently has a consensus rating of “Buy” and a consensus price target of $21.25.

Artiva Biotherapeutics Stock Down 4.3 %

Shares of NASDAQ ARTV opened at $10.06 on Wednesday. Artiva Biotherapeutics has a twelve month low of $9.68 and a twelve month high of $17.31. The firm has a 50 day moving average price of $12.53.

Artiva Biotherapeutics (NASDAQ:ARTV) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.92) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.24). On average, equities analysts forecast that Artiva Biotherapeutics will post -4.6 EPS for the current year.

Hedge Funds Weigh In On Artiva Biotherapeutics

A number of large investors have recently made changes to their positions in the stock. RA Capital Management L.P. bought a new position in shares of Artiva Biotherapeutics in the third quarter worth approximately $152,234,000. Geode Capital Management LLC purchased a new position in Artiva Biotherapeutics during the 3rd quarter valued at about $4,774,000. Samsara BioCapital LLC bought a new stake in shares of Artiva Biotherapeutics in the 3rd quarter worth approximately $4,506,000. Wellington Management Group LLP bought a new position in shares of Artiva Biotherapeutics during the third quarter valued at $2,912,000. Finally, RTW Investments LP purchased a new position in Artiva Biotherapeutics in the third quarter worth about $2,300,000.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.